Research Study
ResistAid™ from Lonza to enhance immune response – Download new publication now!
New research demonstrates the ability of ResistAid™, Lonza’s proprietary, arabinogalactan-based immune support ingredient, to increase the antibody response in healthy adults after exposure to the Tetanus vaccine. Conducted at a dosage of 1.5 g/day, the study finds the efficacy of ResistAid™ at a significantly lower dosage, as compared to the 4.5 g/day that was previously found to be effective. The findings are published in the Journal of the American College of Nutrition, and can be found here: http://www.tandfonline.com/doi/full/10.1080/07315724.2013.839907.
